Clearstead Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Clearstead Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.7K	Buy	+145	New	+$33.9K	﹤0.01%	1586
2026 Q1	–	Sell	-2,677	Closed	-$571K	–	2292
2025 Q4	$571K	Buy	2,677 +1,860	+228%	+$384K	0.01%	619
2025 Q3	$162K	Sell	817 -32	-4%	-$5.97K	﹤0.01%	924
2025 Q2	$147K	Buy	849 +791	+1,364%	+$129K	﹤0.01%	962
2025 Q1	$9.04K	Hold	58	–	–	﹤0.01%	1626
2024 Q4	$7.99K	Sell	58 -1,085	-95%	-$143K	﹤0.01%	1633
2024 Q3	$171K	Sell	1,143 -21	-2%	-$2.84K	﹤0.01%	904
2024 Q2	$159K	Buy	1,164 +109	+10%	+$14.8K	﹤0.01%	887
2024 Q1	$139K	Buy	1,055 +140	+15%	+$20K	0.01%	530
2023 Q4	$115K	Buy	915 +70	+8%	+$6.98K	0.01%	559
2023 Q3	$79.1K	Sell	845 -316	-27%	-$29.6K	﹤0.01%	607
2023 Q2	$104K	Buy	1,161 +541	+87%	+$47.1K	0.01%	572
2023 Q1	$66.5K	Buy	+620	New	+$70.9K	﹤0.01%	596

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Clearstead Advisors's ASND Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 145 shares worth $38.7K. The stake represents ﹤0.01% of the portfolio and ranks #1586 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ASND as recently as Q4 2025.

Clearstead Advisors first reported a position in ASND in Q1 2023 and has held it in 13 quarters since. The position peaked at $571K in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Clearstead Advisors held 145 shares of Ascendis Pharma A/S worth $38.7K as of Q2 2026.
Ascendis Pharma A/S was a new Clearstead Advisors position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1586 holding.
Clearstead Advisors first reported a position in Ascendis Pharma A/S in Q1 2023 and has held it in 13 quarters since.
Clearstead Advisors's Ascendis Pharma A/S position peaked at $571K in Q4 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.